-
admin
Posts
Ractigen Therapeutics Announces ADA 2026 Late-Breaking Presentation Highlighting saRNA as a New Frontier in Obesity Control
Breakthrough preclinical data demonstrate that LiCO-saUcp1 effectively turns white fat into calorie-burning brown fat, driving massive fat loss while fully preserving lean muscle mass and...
New Again Houses® Welcomes New Cash Home Buyer in Sarasota, FL
Multi-Faceted Real Estate Business Celebrates Continued Success with the Opening of Its 66th Cash Home Buying Franchise in Sarasota, FL SARASOTA, Fla., June 05, 2026...
New Again Houses® Welcomes New Cash Home Buyer in Pinellas County, FL
Multi-Faceted Real Estate Business Celebrates Continued Success with the Opening of Its 65th Cash Home Buying Franchise in Pinellas County, FL ST. PETERSBURG, Fla., June...
UREVO Debuts Smart Wellness Pop-Up in SoHo
Three-day public experience during New York Tech Week showcases the future of active work and recovery NEW YORK, June 05, 2026 (GLOBE NEWSWIRE) — New...
TerraSpark Energy Campus Wins $18.5M DOE Grant for West Virginia Power and Carbon Capture Project
Project will deliver 1.6 GW of reliable, low-emission, affordable baseload power with next-generation carbon capture technology MOUNT STORM, W.Va., June 05, 2026 (GLOBE NEWSWIRE) —...
Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind’s Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with Automated Insulin Delivery (AID) Systems
Builds on recent FDA approval (May 29, 2026) of Afrezza for use in children and adolescents aged 6 and older living with type 1 and...
Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026
Presentations will feature clinical results for ribupatide, a GLP-1/GIP receptor dual agonist being developed as a once-weekly injection and a once-daily oral pill for the...
Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study
•Translational data presented at ADA demonstrate icovamenib’s potential to promote muscle preservation and fat reduction, supporting its broader therapeutic utility in obesity and diabetes, including...
Oban BioPharma Announces Presentation of Late-Breaking Abstract at ADA 2026 Highlighting OBT-676: A First-in-Class Small Molecule Combining Dual Amylin and Calcitonin Receptor Full Agonism (DACRA) with GLP-1, GIP and Glucagon (Triple-G) Receptor Partial Agonism
STAMFORD, Conn., June 05, 2026 (GLOBE NEWSWIRE) — Oban BioPharma today announced that preclinical data for OBT-676, a lead small-molecule candidate for the treatment of obesity...
Vireo Growth Inc. Completes Acquisition of Bridgewell Agribusiness LLC and Plans to Acquire Dispensaries in Nevada and Maryland
MINNEAPOLIS, June 05, 2026 (GLOBE NEWSWIRE) — Vireo Growth Inc. (CSE: VREO) (OTCQX: VREOF) (“Vireo” or the “Company”), today announced the closing of its previously announced...
